$0.40
0.02% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US37148K1007
Symbol
GBIO
Sector
Industry

Generation Bio Co Stock price

$0.40
-0.02 3.62% 1M
-0.95 70.23% 6M
-0.66 62.08% YTD
-3.13 88.61% 1Y
-5.01 92.57% 3Y
-24.29 98.37% 5Y
-24.29 98.37% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.02%
ISIN
US37148K1007
Symbol
GBIO
Sector
Industry

Key metrics

Market capitalization $26.94m
Enterprise Value $-43.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.50
EV/Sales (TTM) EV/Sales -1.75
P/S ratio (TTM) P/S ratio 1.10
P/B ratio (TTM) P/B ratio 0.37
Revenue growth (TTM) Revenue growth 146.47%
Revenue (TTM) Revenue $24.56m
EBIT (operating result TTM) EBIT $-72.80m
Free Cash Flow (TTM) Free Cash Flow $-85.96m
Cash position $157.56m
EPS (TTM) EPS $-1.08
P/E forward negative
P/S forward 1.80
EV/Sales forward negative
Short interest 2.46%
Show more

Is Generation Bio Co a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Generation Bio Co Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Generation Bio Co forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Generation Bio Co forecast:

Buy
67%
Hold
33%

Financial data from Generation Bio Co

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
25 25
147% 147%
100%
- Direct Costs 4.76 4.76
9% 9%
19%
20 20
319% 319%
81%
- Selling and Administrative Expenses 31 31
24% 24%
126%
- Research and Development Expense 57 57
25% 25%
232%
-68 -68
39% 39%
-277%
- Depreciation and Amortization 4.76 4.76
9% 9%
19%
EBIT (Operating Income) EBIT -73 -73
38% 38%
-296%
Net Profit -72 -72
57% 57%
-293%

In millions USD.

Don't miss a Thing! We will send you all news about Generation Bio Co directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Generation Bio Co Stock News

Neutral
GlobeNewsWire
13 days ago
-  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid-2025 -  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generatio...
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th ...
Neutral
GlobeNewsWire
2 months ago
-  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
More Generation Bio Co News

Company Profile

Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Cameron McDonough
Employees 115
Founded 2016
Website www.generationbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today